BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25003820)

  • 1. BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease.
    Janku F; Vibat CR; Kosco K; Holley VR; Cabrilo G; Meric-Bernstam F; Stepanek VM; Lin PP; Leppin L; Hassaine L; Poole JC; Kurzrock R; Erlander MG
    Oncotarget; 2014 Jun; 5(11):3607-10. PubMed ID: 25003820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.
    Hyman DM; Diamond EL; Vibat CR; Hassaine L; Poole JC; Patel M; Holley VR; Cabrilo G; Lu TT; Arcila ME; Chung YR; Rampal R; Lacouture ME; Rosen N; Meric-Bernstam F; Baselga J; Kurzrock R; Erlander MG; Janku F; Abdel-Wahab O
    Cancer Discov; 2015 Jan; 5(1):64-71. PubMed ID: 25324352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoalphalipoproteinemia and BRAF
    Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
    Janku F; Diamond EL; Goodman AM; Raghavan VK; Barnes TG; Kato S; Abdel-Wahab O; Durham BH; Meric-Bernstam F; Kurzrock R
    Mol Cancer Ther; 2019 Jun; 18(6):1149-1157. PubMed ID: 31015311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
    Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erdheim-Chester disease: a case treated with IFN-α monitored using plasma and urine cell-free DNA.
    Yang Z; Zhao S; Zhou J; Lei S; Hu Z
    Immunotherapy; 2020 Apr; 12(6):379-387. PubMed ID: 32290742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.
    Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB
    Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
    Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
    Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease.
    Hoyt BS; Yan S; Linos KD; Momtahen S; Sriharan A; Tran TN; Tsongalis GJ; O'Meara RR; Green DC; LeBlanc RE
    Exp Mol Pathol; 2019 Dec; 111():104320. PubMed ID: 31639332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
    Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
    Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.
    Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF
    Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAF
    Mirmomen SM; Sirajuddin A; Nikpanah M; Symons R; Paschall AK; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
    Eur Radiol; 2018 Nov; 28(11):4635-4642. PubMed ID: 29736852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.
    Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX
    Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.
    Cangi MG; Biavasco R; Cavalli G; Grassini G; Dal-Cin E; Campochiaro C; Guglielmi B; Berti A; Lampasona V; von Deimling A; Sabbadini MG; Ferrarini M; Doglioni C; Dagna L
    Ann Rheum Dis; 2015 Aug; 74(8):1596-602. PubMed ID: 24671772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of Erdheim-Chester disease with the
    Matsuhisa T; Teranishi M; Tsuyuki Y; Sone M; Sato J
    Nagoya J Med Sci; 2023 Feb; 85(1):150-156. PubMed ID: 36923612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.
    Yuen CA; Bao S; Aung MS; Shishodia R; Kong XT
    Per Med; 2024; 21(2):71-78. PubMed ID: 38275171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma.
    Techavichit P; Sosothikul D; Chaichana T; Teerapakpinyo C; Thorner PS; Shuangshoti S
    Hum Pathol; 2017 Nov; 69():118-122. PubMed ID: 28504206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
    J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
    Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
    Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review.
    Aggarwal A; Taychert M; Hasanin L; Doll D; Basuino MG; Hasanein H
    Oncology (Williston Park); 2023 Jul; 37(7):298-302. PubMed ID: 37499251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.